Announcements Trials

Conditions

Thoracic 7Other 5Lymphoid 1Sarcoma 1

Drug Classes

Anti-CD19 CAR T-cell 14Anti-CD20 14BTK inhibitor 13Anti-CD20-CD3 bispecific 5Anti-CD30 ADC 5Immunomodulatory drugs (IMiDs) 5Anti-PD-1 4Bcl-2 inhibitor 4Nitrogen mustard 3PI3K delta inhibitor 3Anthracycline 2Anti-CD19 2Anti-CD19-CD3 bispecific 2Anti-CD22 ADC 2Anti-CD79B ADC 2Asparagine-specific enzyme 2ALK inhibitor 1Anti-CCR4 1Anti-CD19 ADC 1Anti-CD22 immunotoxin 1Bcr-Abl inhibitor 1EZH inhibitor 1FGFR inhibitor 1HDAC inhibitor 1KMT2A inhibitor 1Proteasome inhibitor 1XPO1 inhibitor 1
ALK inhibitor × Lymphoid × Clear all

1 Announcement

2021-01-14

FDA approves crizotinib for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma

Drug
Xalkori (crizotinib) · ALK inhibitor
Condition
Lymphoid
Data powered by HemOnc (CC BY 4.0) Colophon âš¡